Yago Pico de Coaña

Yago Pico de Coaña

Auto-generated profile, based on publicly available information

Yago Pico de Coaña

Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2013 in Cancer Research
Verified
Journal Article
Closed access
PDF file
YMYumeng Mao
Yumeng Mao
IPIsabel Poschke
Isabel Poschke
EWErik Wennerberg
Erik Wennerberg
YCYago Pico de Coaña
Yago Pico de Coaña
SBSuzanne Egyhazi Brage
Suzanne Egyhazi Brage
RKRolf Kiessling
Rolf Kiessling
Tumors can suppress the host immune system by employing a variety of cellular immune modulators, such as regulatory T cells, tumor-associated macrophages, and myeloid-derived suppressor cells (MDSC). In the peripheral blood of patients with advanced stage melanoma, there is an accumulation of CD14+HLA-DRlo/− MDSC that suppress autologous T cells ex vivo in a STAT-3–dependent manner. However, a precise mechanistic basis underlying this effect is unclear, particularly with regard to whether the MDSC induction mechanism relies on cell–cell contact of melanoma cells with CD14+ cells. Here, we show that early-passage human melanoma cells induce phenotypic changes in CD14+ monocytes, leading them to resemble MDSCs characterized in patients with advanced stage melanoma. These MDSC-like cells potently suppress autologous T-cell proliferation and IFN-γ production. Notably, induction of myeloid-suppressive functions requires contact or close proximity between monocytes and tumor cells. Further, this induction is largely dependent on production of cyclooxygenase-2 (COX-2) because its inhibition in these MDSC-like cells limits their ability to suppress T-cell function. We confirmed our findings with CD14+ cells isolated from patients with advanced stage melanoma, which inhibited autologous T cells in a manner relying up prostaglandin E2 (PGE2), STAT-3, and superoxide. Indeed, PGE2 was sufficient to confer to monocytes the ability to suppress proliferation and IFN-γ production by autologous T cells ex vivo. In summary, our results reveal how immune suppression by MDSC can be initiated in the tumor microenvironment of human melanoma. Cancer Res; 73(13); 3877–87. ©2013 AACR.

1 August 2015 in Trends in Molecular Medicine
Verified
Journal Article
Closed access
YCYago Pico de Coaña
Yago Pico de Coaña
ACAniruddha Choudhury
Aniruddha Choudhury
RKRolf Kiessling
Rolf Kiessling

1 September 2013 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
YCYago Pico de Coaña
Yago Pico de Coaña
IPIsabel Poschke
Isabel Poschke
GGGiusy Gentilcore
Giusy Gentilcore
YMYumeng Mao
Yumeng Mao
MNMaria Nyström
Maria Nyström
RKRolf Kiessling
Rolf Kiessling
Blocking the immune checkpoint molecule CTL antigen-4 (CTLA-4) with ipilimumab has proven to induce long-lasting clinical responses in patients with metastatic melanoma. To study the early response that takes place after CTLA-4 blockade, peripheral blood immune monitoring was conducted in five patients undergoing ipilimumab treatment at baseline, three and nine weeks after administration of the first dose. Along with T-cell population analysis, this work was primarily focused on an in-depth study of the myeloid-derived suppressor cell (MDSC) populations. Ipilimumab treatment resulted in lower frequencies of regulatory T cells along with reduced expression levels of PD-1 at the nine-week time point. Three weeks after the initial ipilimumab dose, the frequency of granulocytic MDSCs was significantly reduced and was followed by a reduction in the frequency of arginase1-producing CD3− cells, indicating an indirect in trans effect that should be taken into account for future evaluations of ipilimumab mechanisms of action. Cancer Immunol Res; 1(3); 158–62. ©2013 AACR.

16 February 2017 in Oncotarget
Verified
Journal Article
Open access
YCYago Pico de Coaña
Yago Pico de Coaña
MWMaria Wolodarski
Maria Wolodarski
IPIsabel Poschke
Isabel Poschke
YYYuya Yoshimoto
Yuya Yoshimoto
YYYuan Yang
Yuan Yang
RKRolf Kiessling
Rolf Kiessling
Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma

3 February 2017 in OncoImmunology
Verified
Journal Article
Open access
RTRossana Tallerico
Rossana Tallerico
CCCostanza Maria Cristiani
Costanza Maria Cristiani
ESElina Staaf
Elina Staaf
CGCinzia Garofalo
Cinzia Garofalo
RSRosa Sottile
Rosa Sottile
ECEnnio Carbone
Ennio Carbone
Despite the success of immune checkpoint blockade in melanoma, the majority of patients do not respond. We hypothesized that the T and NK cell subset frequencies and expression levels of their receptors may predict responses and clinical outcome of anti-CTLA-4 treatment. We thus characterized the NK and T cell phenotype, as well as serum levels of several cytokines in 67 melanoma patients recruited in Italy and Sweden, using samples drawn prior to and during treatment. Survival correlated with low expression of the inhibitory receptor TIM-3 on circulating T and NK cells prior to and during treatment and with the increased frequency of mature circulating NK cells (defined as CD3−CD56dim CD16+) during treatment. Survival also correlated with low levels of IL-15 in the serum. Functional experiments in vitro demonstrated that sustained exposure to IL-15 enhanced the expression of PD-1 and TIM-3 on both T and NK cells, indicating a causative link between high IL-15 levels and enhanced expression of TIM-3 on these cells. Receptor blockade of TIM-3 improved NK cell-mediated elimination of melanoma metastasis cell lines in vitro. These observations may lead to the development of novel biomarkers to predict patient response to checkpoint blockade treatment. They also suggest that induction of additional checkpoints is a possibility that needs to be considered when treating melanoma patients with IL-15.

12 July 2018 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
VUViktor Umansky
Viktor Umansky
GAGosse J. Adema
Gosse J. Adema
Jarek BaranJarek Baran
Jarek Baran
SBSven Brandau
Sven Brandau
JGJo A. Van Ginderachter
Jo A. Van Ginderachter
ZFZvi G. Fridlender
Zvi G. Fridlender